You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Treatment Naive AML

Showing 1 - 25 of 2,819
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia Trial in Tianjin (Daunorubicin Cytarabine liposome for injection, Vyxeos?Daunorubicin Cytarabine liposome

Unknown status
  • Acute Myeloid Leukemia
  • Daunorubicin Cytarabine liposome for injection
  • Vyxeos、Daunorubicin Cytarabine liposome for injection
  • Tianjin, China
    Institute of Hematology and Hospital of Blood Disease, Chinese A
Jun 7, 2021

AML, Adult Trial in Hangzhou, Shanghai, Wuhan (Selinexor, Azacitidine, Venetoclax)

Not yet recruiting
  • AML, Adult
  • Hangzhou, China
  • +3 more
Feb 12, 2023

Acute Myeloid Leukemia Trial in Nanjing (Venetoclax-Decitabine/Azacitidine-Aclarubicin Association,

Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax-Decitabine/Azacitidine-Aclarubicin Association
  • Venetoclax-Decitabine/Azacitidine Association
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Mar 2, 2022

Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML) Trial in Guiyang (Mitoxantrone Hydrochloride liposome

Not yet recruiting
  • Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)
  • Mitoxantrone Hydrochloride liposome injection
  • Cytarabine (LoDAC)
  • Guiyang, Guizhou, China
    The Affiliated Hospital of Guizhou Medical University
Oct 19, 2021

Disease State in Adult Acute Myeloid Leukemia Ineligible for

Recruiting
  • Acute Myeloid Leukemia
    • Luzern 16, Luzern, Switzerland
    • +9 more
    May 2, 2022

    Acute Myelogenous Leukemia, AML Trial in Worldwide (Venetoclax, Cytarabine)

    Completed
    Has Results
    • Acute Myelogenous Leukemia
    • AML
    • Kansas City, Kansas
    • +8 more
    Aug 3, 2022

    MDS, Anemia Trial in Germany (Luspatercept Injection)

    Recruiting
    • Myelodysplastic Syndromes
    • Anemia
    • Luspatercept Injection
    • Berlin, Germany
    • +18 more
    Jan 25, 2023

    Acute Myeloid Leukemia, EBV-Positive Neoplastic Cells Present, HLA-A*0201 Positive Cells Present Trial in Seattle (Aldesleukin,

    Terminated
    Has Results
    • Acute Myeloid Leukemia
    • +4 more
    • Aldesleukin
    • +2 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Oct 15, 2021

    Leukemia, Myeloid Trial in Worldwide (CC-90011, Venetoclax, Azacitidine)

    Completed
    • Leukemia, Myeloid
    • Duarte, California
    • +34 more
    Apr 26, 2022

    Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), MDS (MDS) Trial in Memphis (drug, biological, device)

    Recruiting
    • Acute Lymphoblastic Leukemia (ALL)
    • +7 more
    • Memphis, Tennessee
      St. Jude Children's Research Hospital
    Oct 8, 2021

    Acute Myeloid Leukemia Trial in Nashville (Biopsy of Bone, Cytarabine, Daunorubicin)

    Recruiting
    • Acute Myeloid Leukemia
    • Biospecimen Collection
    • +5 more
    • Buffalo, New York
    • +1 more
    Jan 27, 2023

    Hematological Malignancies Trial in United Kingdom, United States (Magrolimab, Azacitidine)

    Active, not recruiting
    • Hematological Malignancies
    • Duarte, California
    • +26 more
    Dec 7, 2022

    Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in France, United States (SY-1425 (tamibarotene), azacitidine,

    Active, not recruiting
    • Acute Myeloid Leukemia
    • Myelodysplastic Syndrome
    • SY-1425 (tamibarotene)
    • +2 more
    • Hartford, Connecticut
    • +25 more
    May 4, 2022

    Acute Myeloid Leukemia, MDS Trial (IMM01, Azacitidine)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • Myelodysplastic Syndromes
    • (no location specified)
    Nov 21, 2021

    Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) Trial in Worldwide (Lemzoparlimab, Azacitidine, Venetoclax)

    Recruiting
    • Acute Myeloid Leukemia (AML)
    • Myelodysplastic Syndrome (MDS)
    • Birmingham, Alabama
    • +35 more
    Aug 19, 2022

    Acute Myeloid Leukemia (AML) Trial in China (Venetoclax, Azacitidine)

    Recruiting
    • Acute Myeloid Leukemia (AML)
    • Beijing, Beijing, China
    • +23 more
    Aug 12, 2022

    Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia Trial in Los Angeles, Sacramento, Oklahoma City (Azacitidine,

    Recruiting
    • Acute Myeloid Leukemia
    • Recurrent Acute Myeloid Leukemia
    • Los Angeles, California
    • +2 more
    Mar 11, 2022

    Solid Tumors and Hematologic Malignancy Trial in Belgium, Netherlands, United States (INCB059872, all-trans retinoic acid

    Terminated
    • Solid Tumors and Hematologic Malignancy
    • Birmingham, Alabama
    • +14 more
    Jun 29, 2022

    Acute Myeloid Leukemia Trial in Sacramento (Azacitidine, Uproleselan, Venetoclax)

    Recruiting
    • Acute Myeloid Leukemia
    • Sacramento, California
      University of California Davis Comprehensive Cancer Center
    Aug 12, 2022

    Acute Myelocytic Leukemia Trial in Hefei (Unrelated umbilical cord blood, Venetoclax, Decetabine)

    Recruiting
    • Acute Myelocytic Leukemia
    • Unrelated umbilical cord blood
    • +3 more
    • Hefei, Anhui, China
      The First Affiliated Hospital of University of Science and Techn
    Oct 27, 2023

    Acute Myeloid Leukemia (AML) Trial in Worldwide (Placebo, Venetoclax, Cytarabine)

    Active, not recruiting
    Has Results
    • Acute Myeloid Leukemia (AML)
    • Placebo
    • +2 more
    • Tampa, Florida
    • +108 more
    Jul 15, 2022

    Acute Myeloid Leukaemia Trial in Australia, United States (AZD2811, Azacitidine, Venetoclax)

    Terminated
    • Acute Myeloid Leukaemia
    • Denver, Colorado
    • +10 more
    Mar 24, 2022

    Acute Myelogenous Leukemia Trial in United States (MLN4924, Azacitidine)

    Completed
    Has Results
    • Acute Myelogenous Leukemia
    • Birmingham, Alabama
    • +7 more
    Feb 18, 2020

    Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Worldwide (FT-2102 (olutasidenib),

    Active, not recruiting
    • Acute Myeloid Leukemia
    • +2 more
    • FT-2102 (olutasidenib)
    • +2 more
    • Los Angeles, California
    • +59 more
    Mar 2, 2022

    Elderly AML Patients, Unfit, New-diagnosis AML, Acute Myeloid Leukemia Trial in Kunming (Experimental: Venetoclax in combination

    Not yet recruiting
    • Elderly AML Patients
    • +4 more
    • Experimental: Venetoclax in combination with Decitabine (+-sorafenib)
    • Active Comparator: Standard dose of Venetoclax + Azacitidine
    • Kunming, Yunnan, China
      The Second Affiliated Hospital of Kunming Medical University.
    Oct 3, 2023